Aleksey M. Osadchuk

Aleksey M. Osadchuk

Auto-generated profile, based on publicly available information

Aleksey M. Osadchuk

Russian Medical Academy of Continuous Professional Education

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
MOMikhail A. Osadchuk
Mikhail A. Osadchuk
AOAlexey M. Osadchuk
Alexey M. Osadchuk
Erosive and ulcerative lesions of the digestive tract are one of the most pressing problems in the clinic of internal diseases due to the extremely widespread prevalence, the presence of severe complications, often fatal, diagnostic difficulties due to the presence of a large number of asymptomatic pathologies and difficulties in the rational choice of therapy. Particularly noteworthy is the data that during the global pandemic of Covid-19 infection, it is capable, quite often, of causing the development of erosive and ulcerative lesions of the gastrointestinal tract. In this regard, it seems important to use drugs that can not only prevent the occurrence of erosive and ulcerative lesions and strictures throughout the gastrointestinal tract, but also effectively achieve epithelialization of injuries to the mucous membrane of the oral cavity, esophagus, stomach, small and large intestine. One of them is Rebamipid-CZ, which has a fairly high safety and efficacy profile. It seems important to consider the issues of optimizing the prevention and treatment of erosive and ulcerative lesions of various parts of the gastrointestinal tract of various etiologies, taking into account the possibility of using rebamipide both as part of complex therapy and in isolation.

30 September 2020 in Russian Open Medical Journal
Verified
Journal Article
Closed access
IDIgor L. Davydkin
Igor L. Davydkin
TKTatyana P. Kuzmina
Tatyana P. Kuzmina
KNKsenia V. Naumova
Ksenia V. Naumova
RKRais K. Khayretdinov
Rais K. Khayretdinov
ODOlesya E. Danilova
Olesya E. Danilova
EMElizaveta V. Mordvinova
Elizaveta V. Mordvinova
The article is dedicated to contemporary views on the change of endothelial function in the patients with lymphoproliferative disorders prior to, and in the process of, chemotherapeutic treatment. Considering that possibilities of standard examination do not always help identifying subclinical endothelial dysfunction, it is necessary to use specific methods, in particular, to determine the levels of endothelin-1 and vascular endothelial growth factor to monitor endothelial function. The objective of this review is to identify problems and prospects for recognizing early subclinical changes of endothelial function in the patients with lymphoproliferative disorders before and after chemotherapy. Assessing presence and severity of endothelial dysfunction may be useful for determining subclinical stages of cardiovascular damage, stratifying the risk of the patients with confirmed cardiovascular disease, and reducing the likelihood of cardio- and endotheliotoxic effects in patients long after chemotherapy. That is why early detection and immediate therapy of cardiovascular toxicity is currently the most important task in the patients with lymphoproliferative disorders, receiving chemotherapy.

17 October 2018 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
ASAndrey A. Svistunov
Andrey A. Svistunov
MOMiсhail A. Osadchuk
Miсhail A. Osadchuk
NKNatalia Kireeva
Natalia Kireeva
AOAlexey M. Osadchuk
Alexey M. Osadchuk
The prevalence of cholelithiasis, its close pathogenetic connection with metabolic syndrome, high frequency of surgical intervention, significant economic losses put forward this comorbid pathology in a number of leading problems of modern clinical medicine. The factors associated with the metabolic syndrome not only increase the risk of developing cholelithiasis, but also form the basis of non-drug and drug therapy. Metabolic syndrome often determines the occurrence of three common and potentially life-threatening complications of cholelithiasis: acute cholecystitis, acute cholangitis and biliary pancreatitis. Therefore, the solution of this problem is associated with the need for early detection of additional risk factors for cholelithiasis, optimization of the early diagnostic and prognostic model of existing multi-organ pathology with the aim of reducing the progression of the disease and its complications. The data obtained in recent years on the human genome with metabolic syndrome and cholelithiasis make it possible to predict the development of comorbid pathology and to fully ensure the effectiveness of primary prevention.

1 January 2016 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
ESE. S. Skvortsova
E. S. Skvortsova
EBE. A. Borodulina
E. A. Borodulina
AОArray М. Осадчук
Array М. Осадчук
ИНФИЛЬТРАТИВНЫЙ ТУБЕРКУЛЕЗ ЛЕГКИХ, ЯЗВЕННАЯ БОЛЕЗНЬ желудка И ВИЧ-ИНФЕКЦИЯ (КОМОРБИДНОСТЬ И МУЛЬТИМОРБИДНОСТЬ ЗАБОЛЕВАНИЙ)

1 January 2021 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
AOA.M. Osadchuk
A.M. Osadchuk
ILI.D. Loranskaya
I.D. Loranskaya
MOM.A. Osadchuk
M.A. Osadchuk

15 October 2021 in Therapy
Verified
Journal Article
Closed access
OOOsadchuk A.M. Osadchuk
Osadchuk A.M. Osadchuk
MOMaxim M. Osadchuk
Maxim M. Osadchuk
ZZZolotovskaya I.A. Zolotovskaya
Zolotovskaya I.A. Zolotovskaya
MRMoscow Russian Medical Academy Of Continuing Professional Education Of The Ministry Of Healthcare Of Russia
Moscow Russian Medical Academy Of Continuing Professional Education Of The Ministry Of Healthcare Of Russia
SRSamara State Medical University of the Ministry of Healthcare of Russia
Samara State Medical University of the Ministry of Healthcare of Russia